Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Projektbeschreibung

Europäisches Ausbildungsnetz für die translationale Glioblastom-Forschung

Das Glioblastom ist ein sehr aggressiver und tödlicher Hirntumor, an dem 85 % der Erkrankten innerhalb von zwei Jahren sterben. Derzeit gibt es keine wirksame Therapie gegen das Glioblastom, und neue Behandlungsmöglichkeiten werden dringend benötigt. Das im Rahmen der Marie-Skłodowska-Curie-Maßnahmen finanzierte Projekt GLIOTRAIN wird sich auf die Entwicklung eines europäischen Forschungsausbildungsnetzes konzentrieren, das 14 Organisationen aus 8 Ländern umfasst und 15 kreative junge Forschende ausbilden soll. Das Ziel von GLIOTRAIN ist es, neue therapeutische Strategien für die Glioblastom-Behandlung zu entdecken, indem Next-Generation Sequencing, Systemmedizin und integrative Multi-Omics eingesetzt werden, um die Krankheitsresistenzmechanismen zu verstehen. Das Projektnetz wird eine neue Generation von Forschenden auf die translationale Erforschung und die klinische Behandlung des Glioblastoms vorbereiten.

Ziel

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Koordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Netto-EU-Beitrag
€ 1 062 698,40
Adresse
ST STEPHEN'S GREEN 123
2 Dublin
Irland

Auf der Karte ansehen

Region
Ireland Northern and Western Border
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 1 062 698,40

Beteiligte (8)

Partner (14)